greeksoup/ stock research

Doximity, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 6 November 2025: press release. Guidance figures: 2 raised, 2 new. The quarter’s numbers.

Key takeaways

  • Revenue rose 23% year-over-year: Revenue was $168.5 million against $136.8 million a year earlier. Six-month revenue was $314.4 million against $263.5 million. Source
  • Adjusted EBITDA rose 32%: Adjusted EBITDA was $100.8 million against $76.1 million, with a margin of 59.8% against 55.7%. Source
  • Full-year ranges both raised: Both fiscal 2026 ranges, revenue and adjusted EBITDA, were updated upward from the first-quarter release. Source
  • AI tool users grew over 50%: Users of AI Scribe and DoxGPT grew by more than 50% from the prior quarter, according to the CEO's statement in the release. Source
  • Operating expenses rose across lines: Research and development was $30.2 million against $23.2 million, sales and marketing $39.2 million against $34.4 million, and general and administrative $19.0 million against $10.1 million. Source
  • Operating cash flow and FCF rose 37%: Operating cash flow was $93.9 million against $68.3 million, and free cash flow was $91.6 million against $66.8 million. Source

“Our platform continues to grow with new AI tools to save physicians’ time,”

Jeff Tangney, co-founder and CEO of Doximity

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFiscal third quarter ending December 31, 2025between $180 million and $181 millionNew
Adjusted EBITDA SourceFiscal third quarter ending December 31, 2025between $103 million and $104 millionNew
Revenue SourceFiscal year ending March 31, 2026between $640 million and $646 millionRaised from between $628 million and $636 million
Adjusted EBITDA SourceFiscal year ending March 31, 2026between $351 million and $357 millionRaised from between $341 million and $349 million

What changed from last quarter

  • Guidance raised: Fiscal 2026 revenue guidance rose to $640 million to $646 million from $628 million to $636 million. Source
  • Guidance raised: Fiscal 2026 adjusted EBITDA guidance rose to $351 million to $357 million from $341 million to $349 million. Source
  • New guidance: Revenue and adjusted EBITDA guidance was given for the fiscal third quarter ending December 31, 2025, which the prior release did not include. Source

Results and growth drivers

  • Revenue rose 23% year-over-year: Revenue was $168.5 million against $136.8 million a year earlier. Six-month revenue was $314.4 million against $263.5 million. Source
  • Adjusted EBITDA rose 32%: Adjusted EBITDA was $100.8 million against $76.1 million, with a margin of 59.8% against 55.7%. Source
  • Non-GAAP net income margin rose: Non-GAAP net income was $90.0 million against $61.1 million, a margin of 53.4% against 44.7%. Source
  • Per-share earnings both rose: Diluted EPS was $0.31 against $0.22. Non-GAAP diluted EPS was $0.45 against $0.30. GAAP net income was $62.1 million against $44.2 million. Source

Guidance direction

  • Full-year ranges both raised: Both fiscal 2026 ranges, revenue and adjusted EBITDA, were updated upward from the first-quarter release. Source
  • Third-quarter ranges given: Management gave revenue and adjusted EBITDA ranges for the fiscal third quarter, which the prior release did not include. Source

“In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients,”

Jeff Tangney, co-founder and CEO of Doximity

Products and customers

  • AI tool users grew over 50%: Users of AI Scribe and DoxGPT grew by more than 50% from the prior quarter, according to the CEO's statement in the release. Source
  • Network covers most U.S. physicians: The company describes its network members as including more than 80% of U.S. physicians across all specialties and practice areas. Source
  • Retention and large-customer metrics defined: The release defines net revenue retention and the count of customers above $500,000 in trailing 12-month subscription revenue but reports no values for either. Source

Costs and margins

  • Operating expenses rose across lines: Research and development was $30.2 million against $23.2 million, sales and marketing $39.2 million against $34.4 million, and general and administrative $19.0 million against $10.1 million. Source
  • Gross margin held near prior level: GAAP gross margin was 90.3% against 90.0%. Non-GAAP gross margin was 91.9% in both periods. Source
  • Stock-based compensation increased: Stock-based compensation expense was $29.5 million against $17.9 million, and is excluded from the non-GAAP measures. Source
  • Legal and acquisition costs excluded: Legal expenses of $2.9 million and acquisition and related expenses of $1.2 million were excluded from non-GAAP results in the quarter. Source
  • Income tax provision fell: The provision for income taxes was $10.9 million, against $18.0 million a year earlier. Source

Demand and deferred revenue

  • Current deferred revenue declined: Current deferred revenue was $100.0 million at September 30, 2025, against $114.3 million at March 31, 2025. Source
  • Deferred revenue used more cash: The deferred revenue change reduced operating cash flow by $17.2 million in the quarter, against a $9.2 million reduction a year earlier. Source
  • Receivables released cash: The change in accounts receivable added $12.4 million to operating cash flow in the quarter, against a $4.1 million reduction a year earlier. Source

Cash, capital and returns

  • Operating cash flow and FCF rose 37%: Operating cash flow was $93.9 million against $68.3 million, and free cash flow was $91.6 million against $66.8 million. Source
  • Share repurchases rose over six months: Repurchases of common stock were $21.9 million in the quarter against $23.0 million a year earlier. Six-month repurchases were $144.2 million against $74.2 million. Source
  • Cash and securities balances: Cash and cash equivalents were $169.2 million and marketable securities $709.1 million at September 30, 2025. Source
  • Equity-award tax payments increased: Taxes paid on net share settlement of equity awards were $12.6 million in the quarter, against $5.8 million a year earlier. Source

Strategy and investment

  • Acquisition cash paid in quarter: Cash paid for an acquisition was $26.5 million in the quarter. Goodwill rose to $85.0 million and intangible assets to $39.1 million from March 31, 2025. Source
  • Pathway Medical acquisition noted: The prior-quarter release headlined the acquisition of Pathway Medical and pointed readers to the press release for details.
  • Internal software spending increased: Internal-use software development costs were $2.4 million against $1.5 million a year earlier. Source

Coming up, as management said on 6 November 2025

  • Next reported period is fiscal third quarter: The next period covered by guidance is the fiscal third quarter ending December 31, 2025. Source

Risks management discussed

  • Regulatory: Shareholder class action litigation is among the legal matters management excludes from its non-GAAP measures. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.